GLP-1 receptor agonists and SGLT2 inhibitors: The need to shed light on their safety risks real dimension and possible mechanisms
- PMID: 37385011
- DOI: 10.1016/j.jdiacomp.2023.108553
GLP-1 receptor agonists and SGLT2 inhibitors: The need to shed light on their safety risks real dimension and possible mechanisms
Keywords: Clinical practice; GLP-1 receptor agonists; Research; SGLT2 inhibitors; Safety.
Conflict of interest statement
Declaration of competing interest This Commentary has been written independently and the authors did not receive any financial or professional help for its preparation. The authors have given lectures, received honoraria and research support, and participated in conferences, advisory boards, and clinical trials sponsored by many pharmaceutical companies. Yet, the industry had no role in this article, which reflects only the opinion of the authors.
Comment on
-
Effects of semaglutide and empagliflozin on oxygenation, vascular autoregulation, and central thickness of the retina in people with type 2 diabetes: A prespecified secondary analysis of a randomised clinical trial.J Diabetes Complications. 2023 May;37(5):108472. doi: 10.1016/j.jdiacomp.2023.108472. Epub 2023 Apr 5. J Diabetes Complications. 2023. PMID: 37062189 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
